Combinatorial pathway disruption is a powerful approach to delineate metabolic impacts of endocrine disruptors
Kévin Bernal, Charbel Touma, Chedi Erradhouani, Talía Boronat‐Belda, Lucas Gaillard, Sara Al Kassir, Hélène Le Mentec, Corinne Martin‐Chouly, Normand Podechard, Dominique Lagadic‐Gossmann, Sophie Langouët, François Brion, Anja Knoll‐Gellida, Patrick J. Babin, Iva Sovadinová, Pavel Babica, Karine Andréau, Robert Barouki, Jan Vondráček, Paloma Alonso‐Magdalena, Étienne Blanc, Min Ji Kim, Xavier Coumoul
Abstract
The prevalence of metabolic diseases, such as obesity, diabetes, metabolic syndrome and chronic liver diseases among others, has been rising for several years. Epidemiology and mechanistic (in vivo, in vitro and in silico) toxicology have recently provided compelling evidence implicating the chemical environment in the pathogenesis of these diseases. In this review, we will describe the biological processes that contribute to the development of metabolic diseases targeted by metabolic disruptors, and will propose an integrated pathophysiological vision of their effects on several organs. With regard to these pathomechanisms, we will discuss the needs, and the stakes of evolving the testing and assessment of endocrine disruptors to improve the prevention and management of metabolic diseases that have become a global epidemic since the end of last century.